Everest Expands Ophthalmology Portfolio in China - Summary - MDSpire

Everest Expands Ophthalmology Portfolio in China

Everest Medicines acquires rights to presbyopia eye drop

  • June 15, 2026

  • 2 min

Share

Objective:

To develop, manufacture, and commercialize LNZ100, a prescription eye drop for presbyopia, across Greater China.

Approach:
    Key Findings:
    • LNZ100 is designed to improve near vision without overstimulating the ciliary muscle.
    • The drug was well tolerated with no serious treatment-related adverse events reported.
    • Presbyopia prevalence in China reaches nearly 100% by age 52, with limited current treatment options.
    Interpretation:

    Limitations:
    • No drug is currently approved for presbyopia in China.
    • Current treatment options are limited to glasses and invasive surgery.
    Conclusion:

    Everest's transaction aims to expand its ophthalmology portfolio and strengthen business synergies.

    Sources:

Original Source(s)

Everest Expands Ophthalmology Portfolio in China

  • June 15, 2026

Related Content

FDA Clears First Extended Depth of Focus Contact Lens for Presbyopia

Deseyne delivers smooth, continuous focus across near, intermediate, and distance vision, which is enabled by Cataltheia’s patented hyper-refractive central zone, engineered to precisely redirect light in a controlled manner.

Dual-Mechanism Drop Wins FDA Approval

FDA approves Tenpoint Therapeutics’ YUVEZZI eye drop for presbyopia

  • February 2, 2026

  • 2 min
Training Staff for the Presbyopia Journey

Presbyopia isn’t new—but the way we treat it has changed dramatically. As we continue to embrace these advancements, let’s also commit to the one constant that always makes a difference: a well-trained, well-informed team.